Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

References

• World Health Organization (WHO)Global summary of the HIV/AIDS epidemic, 2009 Available from: http://www.who.int/hiv/data/2009_global_summary.pngAccessed September 23, 2011
   Google Scholar
• National Institute of Health - Istituto Superiore di Sanità (ISS)Notiziario dell’Istituto Superiore di Sanità 2010 2010234 Suppl 1 [Italian]
   Google Scholar
• SteinbrookRProviding antiretroviral therapy for HIV InfectionN Engl J Med200134484484611248164
   PubMed Web of Science ®Google Scholar
• SchackmanBRGeboKAWalenskyRPThe lifetime cost of current human immunodeficiency virus care in the United StatesMed Care2006441199099717063130
   PubMed Web of Science ®Google Scholar
• MocroftALedergerberBKatlamaCfor the EuroSIDA study groupDecline in the AIDS and death rates in the EuroSIDA study: an observational studyLancet2003362222912853195
   PubMed Web of Science ®Google Scholar
• The Antiretroviral Therapy Cohort CollaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesLancet200837229329918657708
   PubMed Web of Science ®Google Scholar
• VolberdingPADeeksSGAntiretroviral therapy and management of HIV infectionLancet2010376496220609987
   PubMed Web of Science ®Google Scholar
• FreedbergKALosinaEWeinsteinMCThe cost effectiveness of combination antiretroviral therapy for HIV diseaseN Engl J Med200134482483111248160
   PubMed Web of Science ®Google Scholar
• Ministry of Health, National Committee on AIDS – Commissione Nazionale per la lotta contro l’AIDS, Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnosticoclinica delle persone con infezione da HIV-1, Ministero della Salute, luglio 2010. [Italian].
   Google Scholar
• DrummondMFO’BrienBJStoddartGLMethods for the economic evaluation of health care programmes3rd edNew YorkOxford University Press2006
   Google Scholar
• Italian Health Economics Association – Associazione Italiana di Economia Sanitaria (AIES)Italian Guidelines proposal on how to conduct economic evaluation studies of health programsPharmacoeconomics – Italian Research Articles2009118393 [Italian]
   Google Scholar
• Emilia-Romagna Region, Epidemiologic Survey on HIV/AIDS, Regione Emilia-Romagna, Lo stato dell’infezione da HIV/AIDS in emiliaromagna Aggiornamento sull’epidemia e primi risultati del sistema di sorveglianza dell’infezione da HIV al 31/12/2009. [Italian].
   Google Scholar
• SimpsonKNLuoMPChumneyECost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infectionHIV Clin Trials2004529430415562370
   PubMed Web of Science ®Google Scholar
• PezzottiPAngelettiCPublic expenditure on antiretroviral drugs: a budget impact analysis model based on regional data – I determinanti della spesa per antiretrovirali: un modello di analisi di budget impact basato su dati regionali Roma, 16 giugno 2010 [Italian]
   Google Scholar
• GallantJEDeJesusEArribasJRfor the Study 934 GroupTenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIVN Engl J Med2006354325126016421366
   PubMed Web of Science ®Google Scholar
• PozniakALGallantJEDeJesusETenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients virologic, immunologic, and morphologic changes – a 96-week analysisJ Acquir Immune Defic Syndr20064353554017057609
   PubMed Web of Science ®Google Scholar
• ArribasJRPozniakALGallantJETenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJ Acquir Immune Defic Syndr2008471747817971715
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJOnce-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyLancet2008372963964665518722869
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJOnce-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJ Acquir Immune Defic Syndr201053332333220032785
   PubMed Web of Science ®Google Scholar
• SorianoVKöppeSMingroneHProspective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 resultsProgram and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionJuly 19–22, 2009Cape Town, South Africa Abstract LBPEB07
   Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS200923131679168819487905
   PubMed Web of Science ®Google Scholar
• LennoxJLDeJesusELazzarinASafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet2009374969279680619647866
   PubMed Web of Science ®Google Scholar
• LennoxJLDejesusEBergerDSfor the STARTMRK InvestigatorsRaltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJ Acquir Immune Defic Syndr2010551394820404738
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakALfor the 903 Study GroupEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trialJAMA2004292219120115249568
   PubMed Web of Science ®Google Scholar
• PostFAMoyleGJStellbrinkHJRandomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyJ Acquir Immune Defic Syndr2010551495720431394
   PubMed Web of Science ®Google Scholar
• SquiresKYoungBDeJesusESimilar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/r in HIV-1 infected patients: 84 week results of the ARIES trialProgram and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionJuly 19–22, 2009Cape Town, South Africa Abstract WELBB103
   Google Scholar
• SmithKYPatelPFineDfor the HEAT Study TeamRandomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatmentAIDS200923121547155619542866
   PubMed Web of Science ®Google Scholar
• PulidoFEstradaVBarilJGLong-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeksHIV Clin Trials2009102768719487177
   PubMed Web of Science ®Google Scholar
• EQ-5D [homepage on the Internet]Rotterdam, The NetherlandsEuroQol Group Available from: http://www.euroqol.orgAccessed September 23, 2011
   Google Scholar
• RavasioRCost-effectiveness analysis of emtrcitabine/tenofovir disoproxil plus efavirenz vs other antiretroviral regimes in fist line treatment of HIV patientGiornale Italiano di Health Technology Assessement201031111 [Italian]
   Google Scholar
• GazzardBfor the BHIVA Writing CommitteeBritish HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapyHIV Med2006748750317105508
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency – Agenzia Italiana del FarmacoNegoziazione e rimborsabilità Available at: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0Accessed September 23, 2011 [Italian]
   Google Scholar
• GarattiniLTediosiFDi CintioEYinDParazziniFfor Gruppo di Studio ARCA (AIDS Resources and Costs Analysis)Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapyAIDS Care200113673374111720643
   PubMed Web of Science ®Google Scholar
• ISTAT Istituto Nazionale di Statistica Available at: http://seriestoriche.istat.it/index.php?id=7&user_100ind_pi1[id_pagina]=70&cHash=468e508f3b1982a1c919b740b8f13d66Accessed on February 1, 2011
   Google Scholar
• So.Re.Sa.SpA – Società Regionale per la SanitàPharma Annuario112010
   Google Scholar
• JonssonBChanging health envìronment: the challenge to demonstrate cost-effectiveness of new compoundsPharmacoeconomics200422 Suppl 451015876007
   PubMed Web of Science ®Google Scholar
• LucioniCRavasioRHow to evaluate the results of a pharmacoeconomic study?Pharmacoeconomics – Italian Research Articles200463121130
   Google Scholar
• MessoriASantarlasciBTrippoliSVaianiMClinical benefit and economic value: methodology and an economic applicationPharmacoeconomics – Italian Research Articles2003525367
   Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• D’Arminio MonforteALepriACRezzaGInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naïve PatientsAIDS20001449950710780712
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med2000133213010877736
   PubMed Web of Science ®Google Scholar
• BangsbergDRPerrySCharleboisEDNon-adherence to highly active antiretroviral therapy predicts progression to AIDSAIDS2001151181118311416722
   PubMed Web of Science ®Google Scholar
• LimaVDHarriganRBangsbergDRThe combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over timeJ Acquir Immune Defic Syndr20095052953619223785
   PubMed Web of Science ®Google Scholar
• AntinoriACozzi-LepriAAmmassariARelative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAARTAntivir Ther2004929129615134192
   PubMed Web of Science ®Google Scholar
• MoeremansKHemmettLHjelmgrenJAllegriGSmetsECost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UKPharmacoeconomics201028 Suppl 114716721182349
   PubMed Web of Science ®Google Scholar
• MoeremansKAnnemansLLöthgrenMCost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UKPharmacoeconomics201028 Suppl 110712821182347
   PubMed Web of Science ®Google Scholar
• SimpsonKNStrassburgerAJonesWJDietzBRajagopalanRComparison of Markov model and discrete-event simulation techniques for HIVPharmacoeconomics200927215916519254048
   PubMed Web of Science ®Google Scholar
• RizzardiniGRestelliUBonfantiPThe cost of HIV disease in Northern Italy: the payer’s perspectiveJ Acquir Immune Defic Syndr201157321121721546850
   PubMed Web of Science ®Google Scholar
• ColomboGLGaetaGBViganòMDi MatteoSA cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in ItalyClinicoecon Outcomes Res20113374621935331
   PubMedGoogle Scholar